Literature DB >> 234499

Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor.

J P Allain, H A Cooper, R H Wagner, K M Brinkhous.   

Abstract

Present methods for assay of platelet aggregating agents use freshly prepared platelets. Much time is spent in daily preparation of platelets and standardization presents problems. The preparation of fixed washed platelets (FWP) and their use in two bioassays are described in this report. Washed human platelets were fixed for 48 hours with 4 per cent paraformaldehyde, washed twice in phosphate buffer, pH 6.4, and stored at 4 degrees C. Aggregation of FWP was studied with a macroscopic test and a light absorbance measurement. FWP did not aggregate with adenosine diphosphate, collagen, adrenalin, and thrombin. FWP aggregated with bovine or porcine plasma, poly-L-lysine, and ristocetin with normal human plasma but not with von Willebrand's disease plasma. These observations confirm the direct aggregating effect of these agents. Macroscopic aggregation times were dependent on the amount of aggregating agent (bovine plasma, normal human plasma). A quantitative assay for bovine platelet aggregating factor (PAF) and von Willebrand factor (vWF) with FWP was developed. The ability of FWP to aggregate remained unchanged after 1 month of storage at 4 degrees C. Ristocetin alone caused a decrease in light transmission of FWP suspensions, depending upon the concentration of ristocetin, but did not cause aggregation. FWP constitute a stable reagent suitable for quantitative measurement of PAF and vWF.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 234499

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  30 in total

1.  Effects of thrombin treatment of preparations of factor VIII and the Ca2+-dissociated small active fragment.

Authors:  H A Cooper; F F Reisner; M Hall; R H Wagner
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

2.  Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of the proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand's disease.

Authors:  C S Jenkins; D R Phillips; K J Clemetson; D Meyer; M J Larrieu; E F Lüscher
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

3.  von Willebrand protein facilitates platelet incorporation in polymerizing fibrin.

Authors:  J Loscalzo; A Inbal; R I Handin
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

4.  Structural analysis of factor VIII antigen in von Willebrand disease.

Authors:  R L Nachman; E A Jaffe; C Miller; W T Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

5.  Human platelet membrane receptor for bovine von Willebrand factor (platelet aggregating factor): an integral membrane glycoprotein.

Authors:  H A Cooper; K J Clemetson; E F Lüscher
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

6.  Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin.

Authors:  J Koutts; P N Walsh; E F Plow; J W Fenton; B N Bouma; T S Zimmerman
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

7.  Exposure of platelet fibrinogen receptors by ADP and epinephrine.

Authors:  J S Bennett; G Vilaire
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

8.  Antibody nature of circulating inhibitor of plasma von Willebrand factor.

Authors:  R D Stratton; R H Wagner; W P Webster; K M Brinkhous
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

9.  Immunoinhibition of ristocetin-induced platelet aggregation.

Authors:  R L Nachman; E A Jaffe; B B Weksler
Journal:  J Clin Invest       Date:  1977-01       Impact factor: 14.808

10.  Susceptibility to atherosclerosis in aortas and coronary arteries of swine with von Willebrand's disease.

Authors:  T R Griggs; R L Reddick; D Sultzer; K M Brinkhous
Journal:  Am J Pathol       Date:  1981-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.